University College London and Ondine Biopharma Announce Breakthrough Staphyloccocal Photodisinfection Technology



    - Most potent photodisinfection agent known today -

    LONDON and VANCOUVER, Oct. 9 /CNW/ - UCL Business PLC, and Ondine
Biopharma Corporation (TSX: OBP; AIM: OBP) today announced an important
advance in photo-disinfection technology used to kill staphylococci such as
methicillin-resistant Staphylococcus aureus (MRSA). In a multi-year
collaborative research effort, scientists developed a nanotechnology-based
photosensitizer that dramatically enhanced antimicrobial lethality at very
small unit doses. The results of the research were published in the Royal
Society of Chemistry's Journal of Materials Chemistry, 2007, 17, 3739-3746
and, because of the importance of the advancement, this publication has been
selected for inclusion in the Royal Society of Chemistry's journal Chemical
Biology Research Articles.
    "The new nanoparticle photosensitizer is the most potent light-activated
antimicrobial agent known to date," said Dr. Cale Street, Director of
Research, Ondine Biopharma. "By covalently attaching gold nanoclusters to an
existing photosensitizer, we were able to dramatically boost bacterial killing
efficacy. We can now use very low concentrations of photosensitizer to achieve
greater than 99.99% eradication of bacteria in seconds to minutes, improving
our ability to develop photodisinfection-based products for the clinical
treatment of infections in wounds, burns, and other conditions."
    "This development is the culmination of an intensive, cross-functional
research effort to develop next-generation anti-MRSA photodisinfection
agents," said Professor Michael Wilson, Division of Microbial Diseases,
University College London. "As resistance to antibiotics continues to increase
in most of the major human pathogens, this powerful technology has great
potential in the struggle against the growing prevalence of hospital-acquired
infections."
    Ondine Biopharma owns exclusive rights to worldwide patent applications
covering this photodisinfection technology. With widespread antimicrobial
indications including eradication of MRSA from the nose and other areas,
treatment of conditions such as periodontal diseases, otitis externa, nailbed
fungus and the disinfection of burns and wounds.

    About UCL Business PLC

    UCL Business PLC (UCLB) is the organisation responsible for
commercializing research generated within University College London (UCL) and
associated organisations. It is primarily responsible for protecting
inventions and transacting commercial activity including options, licences and
collaborative commercial research associated with the University. UCLB also
has responsibility for creating and spinning-out companies from UCL. UCLB is
wholly-owned by UCL and operates as an independent company with its own Board
of Directors.

    About Periowave(TM) and Photodisinfection

    Periowave(TM) is a Photodisinfection system developed by Ondine that
utilizes low-intensity lasers and wavelength-specific, light-activated
photosensitive compounds to specifically target and destroy microbial
pathogens and reduce the symptoms of disease. The compounds are topically
applied and lasers of appropriate wavelength and intensity are used to
disinfect the treatment site. The Company's Periowave(TM) photodisinfection
system is currently approved in Canada for nasal eradication of pathogenic
bacteria such as MRSA and the oral treatment of periodontitis, gingivitis,
peri-implantitis, peri-mucositis, endodontics, and in the European Union for
nasal eradication of MRSA, adult periodontitis, endodontics and
peri-implantitis. The photodynamic disinfection technologies were developed by
Professor Michael Wilson and colleagues at the Eastman Dental Institute,
University College London, and licensed to Ondine by UCL Business PLC,
University College London. Full text of the research publication described
above can be found at J. Mater. Chem., 2007, 17, 3739-3746. Additional
information about Periowave(TM) is available at www.periowave.com.

    About Ondine Biopharma Corporation

    Ondine is developing non-antibiotic therapies for the treatment of a
broad spectrum of bacterial, fungal and viral infections. The Company is
focused on creating and commercializing leading edge products utilizing its
patented light-activated technology. Photodisinfection provides broad-spectrum
antimicrobial efficacy without encouraging the formation and spread of
antibiotic resistance. The Company is headquartered in Vancouver, British
Columbia, Canada, with a research laboratory in Bothell, Washington, USA, and
an international office in St. Michael, Barbados. For additional information,
please visit the Company's website at: www.ondinebiopharma.com

    Forward-Looking Statements:

    Certain statements contained in this release containing words like
"believe", "intend", "may", "expect" and other similar expressions, are
forward-looking statements that involve a number of risks and uncertainties.
Factors that could cause actual results to differ materially from those
projected in the Company's forward-looking statements include the following:
market acceptance of our technologies and products; our ability to obtain
financing; our financial and technical resources relative to those of our
competitors; our ability to keep up with rapid technological change;
government regulation of our technologies; our ability to enforce our
intellectual property rights and protect our proprietary technologies; the
ability to obtain and develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical milestones
in key products and other risk factors identified from time to time in the
Company's filings.

    The TSX Exchange has not reviewed and does not accept responsibility for
    the adequacy or accuracy of this release.





For further information:

For further information: Carolyn Cross, President and Chief Executive
Officer, Ondine Biopharma Corporation, (604) 669-0555,
ccross@ondinebiopharma.com; Christina Bessant, Investor Relations, The Equicom
Group Inc., (416) 815-0700 ext. 269, cbessant@equicomgroup.com; Irma
Gomez-Dib, Media & Investors Relations, FD International, (212) 850-5761,
Irma.gomez.dib@fd.com; Nominated Adviser, Neil Johnson/Ryan Gaffney, Canaccord
Adams Ltd, +44(0)20 7050 6500

Organization Profile

ONDINE BIOPHARMA CORPORATION

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890